Pierre Fabre Medicament Australia Pty Limited was established in Australia in 2001, as a fully owned subsidiary of the international parent company  Pierre Fabre Group is the owner of Pierre Fabre Medicament International with its workforce of 9,700 men and women who carry the company's ambitions and challenges. Our business is all about giving a global response to healthcare professionals and patients. To achieve this, various divisions with innovative solutions are constantly being looked into. Oncology is among the most important divisions of Pierre Fabre Medicament. While establishing the company in Australia, the flagship oncology product NAVELBINE was approved for marketing and listed on the PBS.  Pierre Fabre Oncologie is a division fully dedicated to the clinical and commercial development of the anti-cancer drugs of the company all over the world. Its relationship with the oncology community, based in excellence in the areas of clinical research and therapeutics has made Pierre Fabre one of the leading groups in the area of cancer in Europe. Some figures regarding Pierre Fabre Oncologie :
|
|
|
